4//SEC Filing
Lucchino David L. 4
Accession 0000950170-23-065866
CIK 0001703647other
Filed
Nov 21, 7:00 PM ET
Accepted
Nov 22, 4:05 PM ET
Size
21.6 KB
Accession
0000950170-23-065866
Insider Transaction Report
Form 4
Korro Bio, Inc.KRRO
Lucchino David L.
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2023-11-03+5,600→ 18,274 total - Award
Common Stock
2023-11-03+6,000→ 24,274 total - Sale
Common Stock
2023-11-10$39.59/sh−373$14,767→ 23,864 total - Sale
Common Stock
2023-11-10$46.23/sh−34$1,572→ 23,306 total - Sale
Common Stock
2023-11-10$37.92/sh−37$1,403→ 24,237 total - Sale
Common Stock
2023-11-10$41.94/sh−41$1,720→ 23,823 total - Sale
Common Stock
2023-11-10$45.53/sh−67$3,050→ 23,340 total - Exercise/Conversion
Restricted Stock Units
2023-11-03−5,600→ 0 total→ Common Stock (5,600 underlying) - Sale
Common Stock
2023-11-10$43.17/sh−225$9,714→ 23,598 total - Sale
Common Stock
2023-11-10$44.01/sh−191$8,407→ 23,407 total
Footnotes (10)
- [F1]Reflects shares of the Issuer's common stock received upon vesting of restricted stock units ("RSUs") granted January 26, 2023 as adjusted for a 1-for-50 reverse stock split effected by the Issuer on November 3, 2023.
- [F10]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.07 to $46.00, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request.
- [F2]Total number of shares of common stock is adjusted for a 1-for-50 reverse stock split effected by the Issuer on November 3, 2023.
- [F3]Reflects shares of the Issuer's common stock received upon execution of a separation agreement effective November 3, 2023 resulting in vesting of performance RSUs granted April 11, 2022, as adjusted for the 1-for-50 reverse stock split effected by the Issuer on November 3, 2023.
- [F4]Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person.
- [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.575 to $37.955, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request.
- [F6]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.155 to $40.00, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request.
- [F7]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.45 to $42.00, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request.
- [F8]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.75 to $43.625, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request.
- [F9]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $43.87 to $44.175, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request.
Documents
Issuer
Korro Bio, Inc.
CIK 0001703647
Entity typeother
Related Parties
1- filerCIK 0001785288
Filing Metadata
- Form type
- 4
- Filed
- Nov 21, 7:00 PM ET
- Accepted
- Nov 22, 4:05 PM ET
- Size
- 21.6 KB